Sumitomo Chemical and Sumitomo Pharmaceuticals have reached agreement toset up joint drug manufacturing plants due to growing demand for the latter's products. The plants will be based at the former's Oita prefecture site and are expected to be operational in spring 2003.
Sumitomo Chemical has been supplying Sumitomo Pharmaceuticals with drug raw materials from the Oita manufacturing site for some time, which the latter has processed into finished medicine such as antianxiolitics and angina drugs at its Ibaraki prefecture plant. By bringing the whole process to a single site, the companies foresee added efficiencies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze